Elisa Ignatius
Emory University
7 Papers
Elisa Ignatius is an academic researcher from Emory University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study
Elize Pietersen,Elisa Ignatius,Elizabeth M. Streicher,Barbara Lazaro Mastrapa,Xavier Padanilam,Anil Pooran,Motasim Badri,Motasim Badri,Maia Lesosky,Paul D. van Helden,Frederick A. Sirgel,Robin M. Warren,Keertan Dheda +12 more
TL;DR: In South Africa, substantial numbers of patients with XDR tuberculosis who have failed treatment and have positive sputum cultures are being discharged from hospital and are likely to transmit disease into the wider community.
257
Nebulized Bacteriophage in a Patient With Refractory Mycobacterium abscessus Lung Disease
Rebekah M. Dedrick,K. Freeman,Jan A. Nguyen,Asli Bahadirli-Talbott,M. Cardin,Madison Cristinziano,Bailey E. Smith,Soo Jeong Jeong,Elisa Ignatius,Cheng Ting Lin,Keira A. Cohen,Graham F. Hatfull +11 more
TL;DR: An elderly man with refractory Mycobacterium abscessus lung disease previously developed anti-phage neutralizing antibodies while receiving intravenous phage therapy, and subsequent phage nebulization resulted in transient weight gain, decreased C-reactive protein, and reduced Myc Cobacterium burden.
Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.
Kamunkhwala Gausi,Maxwell Chirehwa,Elisa Ignatius,Richard Court,Xin Sun,Laura Moran,Richard Hafner,Lubbe Wiesner,Susan L. Rosenkranz,Veronique R. de Jager,N. de Vries,Joe Harding,Tawanda Gumbo,Susan Swindells,Andreas H. Diacon,Kelly E. Dooley,Helen McIlleron,Paolo Denti +17 more
TL;DR: Markedly lower isoniazid exposures were observed in participants on combination MDR-TB treatment compared with monotherapy, and the safety implications of these phenomena remain unclear.
6
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results.
Kelly E. Dooley,Bronwyn Hendricks,Nikhil Gupte,Grace L. Barnes,Kim Narunsky,Colleen Whitelaw,Tanya Smit,Elisa Ignatius,Adine Friedman,Susan E. Dorman,Rodney Dawson +10 more
TL;DR: In this paper , the safety and efficacy of pretomanid-rifamycin-pyrazinamide containing regimens among participants with drug-sensitive pulmonary tuberculosis were evaluated.
4
High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial.
Kamunkhwala Gausi,Elisa Ignatius,Veronique R. de Jager,Caryn Upton,Soyeon Kim,Ashley McKhann,Laura Moran,Lubbe Wiesner,F. von Groote-Bidlingmaier,Philip Marzinek,Naadira Vanker,Joseph Yvetot,Samuel Pierre,Susan L Rosenkranz,Susan Swindells,Andreas H Diacon,Eric L. Nuermberger,P. Denti,K. E. Dooley +18 more
TL;DR: This study found negligible bactericidal activity of high-dose isoniazid (15-20 mg/kg) in the majority of participants with tuberculosis caused by katG-mutated M.tb, and found negligible bactericidal activity of high-dose isoniazid (15-20 mg/kg) in the majority of participants with tuberculosis caused by Mycobacterium tuberculosis.
4